UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

COVID-19: Zinc and Angiotensin-Converting Enzyme 2 (ACE2) Deficiencies as Determinants of Risk and Severity of Disease: A Narrative Review

Infectious diseases and therapy, 2021-09, Vol.10 (3), p.1215-1225

Salgo, Miklos P.

2021

Volltextzugriff (PDF)

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

AIDS (London), 2004-09, Vol.18 (13), p.1787-1794

2004

Volltextzugriff (PDF)

Pharmacokinetic Interaction Study of Ritonavir-Boosted Saquinavir in Combination with Rifabutin in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2011-02, Vol.55 (2), p.680-687

2011

Volltextzugriff (PDF)

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

Journal of acquired immune deficiency syndromes (1999), 2005-12, Vol.40 (4), p.404-412

2005

Volltextzugriff (PDF)

Angiotensin-Converting Enzyme 2, Feedback Systems, and COVID-19

Consultant (Hackensack), 2021-04, Vol.60

Salgo, Miklos P.

2021

Volltextzugriff (PDF)

Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) Trials

Clinical infectious diseases, 2006-03, Vol.42 (6), p.870-877

2006

Volltextzugriff (PDF)

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

Journal of acquired immune deficiency syndromes (1999), 2005-12, Vol.40 (4), p.413-421

2005

Volltextzugriff (PDF)

Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012)

The Journal of infectious diseases, 2006-11, Vol.194 (9), p.1319-1322

2006

Volltextzugriff (PDF)

Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview

AIDS research and therapy, 2009-08, Vol.6 (1), p.18-18, Article 18

2009

Volltextzugriff (PDF)

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

Nature reviews. Drug discovery, 2004-03, Vol.3 (3), p.215-225

2004

Volltextzugriff (PDF)

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

AIDS (London), 1999-02, Vol.13 (2), p.213-224

1999

Volltextzugriff (PDF)

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

The New England journal of medicine, 2003-05, Vol.348 (22), p.2186-2195

2003

Volltextzugriff (PDF)

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

The New England journal of medicine, 2003-05, Vol.348 (22), p.2175-2185

2003

Volltextzugriff (PDF)

Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective

AIDS research and human retroviruses, 2006-11, Vol.22 (11), p.1110-1112

2006

Volltextzugriff (PDF)

Thorough QT/QTc Study of Ritonavir-Boosted Saquinavir Following Multiple-Dose Administration of Therapeutic and Supratherapeutic Doses in Healthy Participants

Journal of clinical pharmacology, 2012-04, Vol.52 (4), p.520-529

2012

Volltextzugriff (PDF)

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Critical care medicine, 2001-03, Vol.29 (3), p.503-510

2001

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide

Clinical pharmacokinetics, 2005-01, Vol.44 (2), p.175-186

2005

Volltextzugriff (PDF)

HIV fusion and its inhibition in antiretroviral therapy

Reviews in medical virology, 2004-09, Vol.14 (5), p.321-337

2004

Volltextzugriff (PDF)

Guillain-Barré Syndrome Associated with Immune Reconstitution

Clinical infectious diseases, 2003-05, Vol.36 (9), p.e111-e114

2003

Volltextzugriff (PDF)

Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule

Therapeutic innovation & regulatory science, 2014-07, Vol.48 (4), p.413-419

2014

Volltextzugriff (PDF)

Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function

Journal of acquired immune deficiency syndromes (1999), 2008-03, Vol.47 (3), p.342-345

2008

Volltextzugriff (PDF)

Population Pharmacokinetics of Enfuvirtide in HIV-1-Infected Pediatric Patients Over 48 Weeks of Treatment

Journal of clinical pharmacology, 2007-04, Vol.47 (4), p.510-517

2007

Volltextzugriff (PDF)

A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study

Journal of antimicrobial chemotherapy, 2008-12, Vol.62 (6), p.1374-1378

2008

Volltextzugriff (PDF)

A focus of Rocky Mountain spotted fever within New York City

The New England journal of medicine, 1988-05, Vol.318 (21), p.1345-1348

1988

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(53)
Science & Technology
(53)
Humans
(37)
Biological And Medical Sciences
(32)
Medical Sciences
(32)
Infectious Diseases
(31)
Female
(29)
Hiv Infections - Drug Therapy
(26)
Male
(26)
Adult
(23)
Hiv Envelope Protein Gp41 - Therapeutic Use
(20)
Peptide Fragments - Therapeutic Use
(20)
Hiv
(17)
Hiv Fusion Inhibitors - Therapeutic Use
(17)
Human Immunodeficiency Virus
(17)
Immunology
(17)
Pharmacology. Drug Treatments
(17)
Virology
(17)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(16)
Pharmacology & Pharmacy
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

COVID-19: Zinc and Angiotensin-Converting Enzyme 2 (ACE2) Deficiencies as Determinants of Risk and Severity of Disease: A Narrative Review

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

Pharmacokinetic Interaction Study of Ritonavir-Boosted Saquinavir in Combination with Rifabutin in Healthy Subjects

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

Angiotensin-Converting Enzyme 2, Feedback Systems, and COVID-19

Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) Trials

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012)

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals

Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective

Thorough QT/QTc Study of Ritonavir-Boosted Saquinavir Following Multiple-Dose Administration of Therapeutic and Supratherapeutic Doses in Healthy Participants

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide

HIV fusion and its inhibition in antiretroviral therapy

Guillain-Barré Syndrome Associated with Immune Reconstitution

Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule

Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function

Population Pharmacokinetics of Enfuvirtide in HIV-1-Infected Pediatric Patients Over 48 Weeks of Treatment

A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study

A focus of Rocky Mountain spotted fever within New York City

Suchergebnisse filtern